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Abstract Telomerase was initially considered as a relevant
factor distinguishing cancer from normal cells. During de-
tailed studies, it appeared that its expression and activity is
not only limited to cancer cells however, but in this partic-
ular cells, the telomerase is much more abundant. Thus, it
has become a very promising target for an anticancer ther-
apy. It was revealed in many studies that regulation of
telomerase is a multifactorial process in mammalian cells,
involving regulation of expression of telomerase subunits
coding genes, post-translational protein–protein interac-
tions, and protein phosphorylation. Numerous proto-
oncogenes and tumor suppressor genes are engaged in this
mechanism, and the complexity of telomerase control is
studied in the context of tumor development as well as
aging. Additionally, since numerous studies reveal a corre-
lation between short telomeres and increased genome insta-
bility or cell mortality, the telomerase control appears to be
one of the crucial factors to study in order to improve the
cancer diagnostics and therapy or prevention. Interestingly,
almost 100 % of adenocarcinoma, including breast cancer
cells, expresses telomerase which makes it a good target for
telomerase-related therapy. Additionally, telomerase is also
supposed to be associated with drug resistance. Thus,
targeting the enzyme might result in attenuation of this
phenomenon. Moreover, since stem cells existence was
reported, it must be considered whether targeting telomerase
can bring some serious side effects and result in stem cells
viability or their regenerative potential decrease. Thus, we
review some molecular mechanisms engaged in therapy
based on targeting telomerase in breast cancer cells.
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Introduction
Telomeres are guanine-rich repeated sequences located at
the ends of chromosomes. They function as a biological
clock limiting the cell proliferation potential with every next
cell division (Hayflick limit) [1]. This phenomenon is ac-
companied by cell senescence, mitotic crisis, and/or apopto-
sis [2, 3]. However, most cancer cells reveal a telomere
length maintenance mechanism which is responsible for
telomeres renewal during cell proliferation. Majority of
cancer cells utilize telomerase for this purpose, and the
enzyme contains its integral RNA molecule which consti-
tutes the template for reverse transcription of new telomeric
DNA [4]. Telomerase has been recognized as a relevant
factor distinguishing cancer from normal cells since it is
either undetectable or has low level of activity in normal
somatic cells [5]. Thus, it has become a very promising
target for an anticancer therapy. It was revealed in many
studies that regulation of telomerase in mammalian cells is a
multifactorial process, involving expression of telomerase
subunits coding genes, post-translational protein–protein in-
teractions, and protein phosphorylation [6, 7]. Numerous
proto-oncogenes and tumor suppressor genes are engaged
in this mechanism. Thus the complexity of telomerase con-
trol is studied in the context of stem cell renewal, tumor
development, as well as aging [8–14]. Thus, it is of great
interest to identify the enzyme regulators (tumor suppressors
or oncogenes, etc.) The studies across many tumor types
have shown that the vast majority of tumors (~85 %) express
telomerase [15, 16] and hence, are able to maintain a stable
and homogenous telomere length. Consequently, they can
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avoid replicative senescence. Only just about 15 % of tumors
either do not maintain telomere length or activate alternative
lengthening of telomeres (ALT) [17]. Interestingly, almost
100 % of adenocarcinoma, including breast cancer cells,
express telomerase [18]. Till now, several strategies have been
proposed to control telomerase in cancer cells: antisense tech-
nology against telomerase RNA component (TR) and telome-
rase reverse transcriptase (TERT), ribozymes against TERT,
antiestrogens, progesterone, vitamin D, retinoic acid,
quadruplex stabilizers, telomere and telomerase-targeting
agents, modulation of interaction with other proteins involved
in the regulation of telomerase and telomeres, etc. [19–25].
However, the transcription control of key telomerase subunits
seems to play the crucial role in whole complexes activity and
cancer cells immortality. Interesting results were shown by
Blackburn et al. [26]. In Saccharomyces cerevisiae, the telo-
merase deletion response (TDR), that occurs when telomeres
can no longer be maintained by telomerase, resulted in
upregulation of energy production genes, accompanied by a
proliferation of mitochondria. Finally, a discrete set of genes,
the “telomerase deletion signature”, is uniquely upregulated in
the TDR but not under other conditions of stress and DNA
damage. The telomerase deletion signature genes define new
candidates for involvement in cellular responses to altered
telomere structure or function that might mediate cell death
induction. Thus, it was suggested in numerous studies, that
telomerase silencing is accompanied by abundant genes
expression modulation which implicates that cell death
following telomerase downregulation is not always related to
telomere shortening [26–28].
Telomerase
Human telomerase is a multisubunit ribonucleoprotein that
belongs to the reverse transcriptase (RT) family containing
RT-like motifs. It is composed of seven conservative motifs
and telomerase-specific T motif [29, 30]. The catalytic telo-
merase protein subunit (TERT) is encoded by gene located on
chromosome 5p15.33 [29]. A number of telomere binding
proteins in human were identified [31–33] and shown to play
crucial role in telomere protection. They allow to distinguish
telomeres from damaged DNA by forming telomere structure
with D- and T-loops and therefore prevent them from degra-
dation and fusion. Additionally, the complex is safeguarded
by shelterin that enables recognition of the natural chromosome
ends from DNA breaks. It also regulates telomerase-based
telomere maintenance. Shelterin, a very dynamic structure, is
implicated in the generation of T-loops, and control of the
telomeric DNA synthesis [34]. All six shelterin subunits
(TRF1, TRF2, Rap1, TIN2, TPP1, and POT1) can be found
in a single complex in fractionated nuclear extracts [35, 36].
The components specifically localize to telomeres. They are
abundant at telomeres throughout the cell cycle and they do not
function elsewhere in the nucleus. In addition, telomeres
contain a large number of nonshelterin proteins which
unlike the subunits of shelterin have other nontelomeric
functions [34].
Regulation of telomerase activity and expression occurs
at many levels, including transcription, alternative splicing,
chaperone-mediated folding, phosphorylation, nuclear
translocation of each subunit, assembly of the telomerase
complex, and its accessibility to telomeres [37, 38]. How-
ever, as reported so far, increased telomerase activity is
always correlated with upregulation of the TERT gene and
an increased level of TERT mRNA. The Nobel Prize in
Physiology or Medicine awarded in 2009 to Elizabeth H.
Blackburn, Carol W. Greider, and Jack W. Szostak “for the
discovery of how chromosomes are protected by telomeres
and the enzyme telomerase” highlighted the important role
of telomerase and telomeres in genome stability, immortality,
aging, and cancer.
Telomerase regulation in oncology
Because of significant role of telomerase in tumor develop-
ment as well aging, it is of great interest to identify the
enzyme expression/activity regulators. Moreover, since high
telomerase expression is characteristic for stem cells but not
for differentiated cells, the study of regulatory pathways that
control telomerase expression may be critical for mainte-
nance of the stem cell status. Thus, some potential side
effect must be considered (Fig. 1). We do believe in signif-
icant beneficial effects of telomerase elimination in cancer
cells that should be accompanied by induction of senes-
cence, mitotic crisis, and apoptosis or autophagy. However,
we are aware of the protection system of those cells which is
manifested by induction of ALT.
Transactivation of telomerase, essential for cells
immortalization, is supposed to be one of the reasons for
cancer transformation. There are many studies describing
exogenous factors influencing TERT, e.g., several viruses are
known to be involved in tumorigenesis of infected tissues
which was already widely discussed [5, 39, 40]. Thus, due
to the complexity of the telomerase regulation, there is a great
challenge on one hand, but on the other hand, there are a lot of
potential ways to target and thus, stop the “immortality
enzyme.”
Regulation of telomerase transcription in breast cancer
Transcriptional mechanism of telomerase regulation
(Table 1) was revealed in numerous studies and abundance
of transcription factors sites in TERT promoter was localized
[29]. For example, involvement of c-myc in telomerase
regulation was widely investigated, and its role in TERT
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gene expression induction was confirmed in many studies
[12, 41, 42]. Additionally, both, human epidermal growth
factor-2 (Her2) and ER81 (transcription factor involved in
ontogenesis and breast tumor formation) [43], have been
suggested to cause a synergistic increase in the transcrip-
tional induction of TERT in breast cancer patients [44]. It
was suggested that TERT gene expression could be induced
by activating mutations of oncogenes such as HER2/Neu,
Ras, and Raf [45]. Consequently, it was shown that
HER2/Neu might become another target for a combined
anticancer therapy in the context of telomerase elimination.
Among other factors that contribute to telomerase expres-
sion induction, leptin (significant breast cancer risk factor)
[46], epidermal growth factor receptor (EGFR) [47], and
estrogen receptors ERa and ERb [48] were found. These
receptors are ligand-dependent transcription factors capable
of direct interaction between the hormone–receptor complex
and estrogen responsive elements [49]. Their status signifi-
cantly contributes to breast cancer development, diagnosis,
and prognosis [50]. Estrogens were shown to activate telo-
merase via direct and indirect effects on the TERT promoter
and suggested hormonal control of telomerase activity,
cellular senescence and aging as well as estrogen-induced
carcinogenesis [51]. Additionally, latest reports show that
anticarcinogenic plant compound, indole-3-carbinol, that
can modulate steroid hormone-mediated processes, can also
trigger TERT downregulation in breast cancer MCF7 cells
[52]. As suggested, this compound might induce TERT
inhibition-related cell cycle arrest.
There are also some other factors that may repress telo-
merase in breast cancer cells. BRCA1, playing a role in
maintaining genomic stability and acting as a tumor sup-
pressor, was found to interact with c-myc (TERT inducer). It
was indicated that overexpression of the BRCA1 gene in-
hibits TERT expression and telomerase enzymatic activity in
various cell types via the inhibition of c-myc-mediated
transactivation of the TERT promoter [53, 54]. Furthermore,
it is suggested that BRCA1 and Nmi (N-myc and c-myc
interacting protein) can form a complex with c-myc in vitro
and in vivo [55]. BRCA1 is also involved in telomere
shortening independently of telomerase [54, 56]. BRCA1
interacts with TRF1 and TRF2, and it is suggested that it
regulates the length of the 3′ G-rich overhang by being
recruited to the telomere in a Rad50-dependent manner
[56]. It was demonstrated that p53 repressed telomerase
activity through downregulation of TERT transcription
and that interaction of p53 with Sp1 or other transcrip-
tion factors may be involved in this regulation [57, 58].
The p73 protein, structural and functional homologue of
p53, encoded by TP73 gene was also suggested to con-
tribute to cell cycle regulation, apoptosis, and TERT
promoter repression [59, 60]. Additionally, dexamethasone
was reported to inhibit telomerase expression similarly to a
“stress hormone”—cortisol [61]. Similarly, genistein
(phytoestrogen) was shown to cause similar effect [62].
Among other factors that contribute to telomerase
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Fig. 1 Possible telomerase
modulation effects. Numerous
strategies against telomerase
were developed that are
supposed to work at different
levels and specificity. However,
all potential telomerase-
targeting agents must be
considered in the context of
potential side effects
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Telomerase and cancer treatment at the molecular level
It is suggested that the loss of proliferative potential
observed in human cells lacking telomerase may be considered
as a potential mechanism helping to avoid cancer. This is
hypothesized since cancer arises aftermultiple geneticmutations
that altogether cause the cell escape from replication, migration,
and growth control. Thus, a lack of telomerase would limit the
growth of tumors by causing continually dividing cells
to shorten their telomeres and to die before starting to
spread. This is why telomerase inhibitors seem to be
promising factors eliminating cancer cells (Fig. 2).
Recently, several natural-derived compounds were found to
exhibit antitumor activity in the context of telomerase regulation.
One of them is butein (3,4,2′,4′-tetrahydroxychalcone), a poly-
phenolic compound causing downregulation of telomerase
through suppression of TERT gene expression. Moreover, it
was demonstrated that this suppression is c-myc-dependent,
because butein prevents c-myc binding to TERT promoter [65]
which is followed by TERT expression decrease. Comparing
telomerase-positive and ALT cells, it was found that c-myc
activity was lower in ALT cells but there was no difference in
the gene expression. Interestingly, it was demonstrated that leptin
activated telomerase in a dose-dependent manner, upregulated
the expression of TERT at mRNA and protein levels. On the
other hand, the blockade of signal transducer and activator of
transcription 3 (STAT3) phosphorylation significantly
counteracted leptin-induced TERT transcription and protein
expression. Thus, a new mechanism of the proliferative effect
of leptin on breast cancer cells was suggested, and a new
explanation of obesity-related breast cancer was hypothesized
[46].
Another compound, pectenotoxin-2 (PTX2), most toxic
compound from the group of pectenotoxins (found in ma-
rine sponges and shellfish) was shown to downregulate
telomerase activity through suppression of TERT gene ex-
pression at the transcriptional level. It was shown that
PTX2-dependent attenuation of TERT expression was me-
diated through suppression of c-myc- and Sp1-binding on
the regulatory regions of TERT [66]. Both factors influenced
telomerase also on posttranscriptional level by attenuation
of Akt phosphorylation, thereby reducing the phosphoryla-
tion and nuclear translocation of TERT [65, 66]. The inves-
tigation of the effects of PTX on human breast cancer cells
(MDA-MB-231 and MCF7) revealed a significant suppres-
sion of cell proliferation and induction of G2/M phase arrest
through downregulation of cyclin B1 and cdc2 expression,
as well as through phosphorylation of cdc25C. The in-
creased phosphorylation of ATM and Chk1/2 in a PTX2
dose-dependent manner was also found. Furthermore, treat-
ment with PTX2 increased H2O2 generation with correlated
G2/M arrest revealing that PTX2-induced cell cycle arrest
was not restricted to p53 status in human breast cancer cells
[67]. As demonstrated by Heaphy et al. [68], telomeres were
shorter in more aggressive subtypes, such as luminal B,
HER-2-positive and triple-negative tumors, suggesting that
tumor telomere length may have utility as a prognostic
and/or risk marker for breast cancer. Joseph et al. [69]
revealed that when breast and pancreatic cancer cell lines
were treated with potent telomerase inhibitor, imetelstat
(oligonucleotide, direct enzyme inhibitor) in vitro, telome-
rase activity in the bulk tumor cells and cancer stem cells
subpopulations was inhibited. In vitro treatment with
imetelstat, but not control oligonucleotides, also reduced
the proliferation and self-renewal potential of MCF7
mammospheres and resulted in cell death after <4 weeks
of treatment.
Table 1 Human telomerase regulation
Telomerase inducers
Leptin [45] HBZ (HTLV1 bZIP factor) [92]
EGFR [46] LANA (latency-associated
nuclear antigen) [93]
Survivin* [94] Her2/Neu/Ras/Raf [44]
Sp1 [95] ΔNp73 [96]
Mad1/c-Myc [97, 98] Ets2 [99]
HBX protein (X protein of HBV)
[100]
STAT3 [101]
HPV16 E6 [102] Estrogen receptors (ERs) ERα
and ERβ [47]
ERK/ER81 [28, 44, 103, 104] 17β - estradiol (E2) [47, 50]
Telomerase repressors
Dexamethasone (Dex) [60] Egr-1(early growth response 1)
transcription factor [105]
Gefitinib* [64] TGFβ [106]
Genistein (phytoestrogen)* [61] PTEN [107]
Upstream stimulatory factor (USF)
1 and 2 [108]
IP6* [109]
WT1 (Wilm’s tumor 1 suppressor
gene product) [110]
Imatinib mesylate* [111]
MZF-2 [112, 113] Indole-3-carbinol (I3C)[51]
p53-Sp1 complex [114] BRCA1 gene [52, 53]
p53/p21/Rb/E2F [95] Nmi (N-myc and c-myc
interacting protein)[54]
p73 [115] Rad50 [55]
NFX1-91 [116] Raloxifene [62]
Interferon-γ [117] Melatonin [63]
CTCF [118, 119] Butein (3,4,2′,4′-
tetrahydroxychalcone) [64]
PPARγ (peroxisome proliferator-
activated receptor γ) [120]
Pectenotoxin-2 (PTX2) [65]
PPAR α (peroxisome proliferator-
activated receptor α) [121]
Imetelsat sodium (GRN163L)
[68]
Menin [106] ATRA (all-trans retinoic acid)
[71]
TR antisense oligonucleotides [77] Sulforaphane (SFN) [72]
BIBR1532 [80]
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As reported by Moon et al. [65], gefitinib downregulated
the activation of Akt and subsequent TERT phosphorylation
and translocation into the nucleus in MDA-MB-231 cells.
These results indicate that gefitinib induces loss of telomerase
activity through dephosphorylation of EGFR in MDA-MB-
231 cells showing high expression of EGFR. Similarly,
Papanikolaou et al. [70] showed that silencing of TERT and
HER2 achieved by small interfering RNA technology
increased radiosensitivity of cells. Knockdown of HER2 also
led to increased radiosensitivity and downregulation of
TERT/telomerase. It was confirmed that c-myc and mad1
regulated TERT expression in all irradiated breast cancer cells.
Additionally, it was shown that circulating TERT DNA had a
better diagnostic value than carbohydrate antigen CA 15.3 in
early breast cancer disease and could be a possible candidate
as a tumor marker in patients with infiltrating ductal carcino-
ma positive to steroid hormonal receptor and with amplifica-
tion of HER-2/Neu [71]. Another natural compound,
genistein, was reported as one of the most promising natural
compounds targeting telomerase. This natural isoflavone
found in soybean products has been reported to downregulate
telomerase activity, to prevent cancer and to contribute to the
apoptosis of cancer cells. It was shown that genistein inhibited
the transcription of TERT in breast MCF10AT benign and
MCF7 cancer cells in a time- and dose-dependent manner.
Three major DNAmethyltransferases (DNMTs; 1, 3a, and 3b)
were decreased in genistein-treated breast cancer cells,
suggesting that this compound might repress TERT by
impacting epigenetic pathways. Thus, it was concluded that
genistein might work, at least in part, through epigenetic
mechanisms of telomerase inhibition and might facilitate ap-
proaches to breast cancer prevention and treatment in a com-
bined therapy. Another compound showing potent telomerase
inhibition is all-trans retinoic acid (ATRA) which was
reported to have significant effect on the morphology and
proliferation rate of the breast cancer SK-BR-3 cells [72]. It
was shown to decrease the cancer cell growth and lower
telomerase activity which was associated with a rapid de-
crease in histone H3-lysine 9 acetylation (H3-K9-Ac) of the
TERT promoter. Further ATRA treatment was shown to in-
duce apoptosis in estrogen receptor-negative breast cancer
cells [72]. Another telomerase-inhibiting natural compound,
sulforaphane (SFN), an isothiocyanate found in cruciferous
vegetables is a common dietary component that reveals
histone deacetylase inhibition activity and significant potential
in cancer prevention. The mechanism of action is supposed to
act through the decrease of DNMTs, especially DNMT1 and
DNMT3a, suggesting that SFN may repress TERT by
impacting epigenetic pathways [73]. Similarly, trichostatin
A, an inhibitor of histone deacetylase, is a well-known
antitumor agent that effectively and selectively induces tumor
growth arrest and apoptosis.
Telomerase, drug resistance, and therapy
Resistance to chemotherapy is one of the principal causes of
cancer mortality and generally appears in a late tumor pro-
gression process. Cellular models of drug resistance have
been useful in identifying the molecular mechanism of this
phenomenon and most of them are derived from a late stage
of cancer. As suggested, the ability to acquire multidrug
resistance (MDR) can arise before the malignant transfor-
mation stage and is preceded by expression of telomerase
and inactivation of p53 and pRb. Thus, the pathways
inactivated during tumorigenesis confer the ability to ac-
quire drug resistance [74]. Telomerase catalytic subunit
expression shows correlations with MDR- and apoptosis-
related genes and is of prognostic significance [75, 76]. The
contribution of telomerase to multidrug resistance was
suggested to result from increased chromosome stability
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and a strong expression of both ABCB1 and ABCC genes
[77]. As reported by Ji et al. [78], TR antisense oligonucle-
otides could downregulate the telomerase activity, increase
radiation-induced DNA damage, and reduce the subsequent
repair. Furthermore, it could inhibit the proliferation and
increase cancer cell radiosensitivity; however, without telo-
mere shortening. Similarly, Cerone et al. [18] demonstrated
that mutated TR coding subunit resulted in an increased
sensitivity of breast cancer cells to anticancer drugs. It was
shown in cells with different initial telomere lengths and
different mechanisms of telomere maintenance. Authors
suggested that dysfunctional TR coding gene affects the
binding of the shelterin complex, disturbs telomere capping,
and induces a DNA damage response. It has been proposed
that the mutant TR might interfere with alternative functions
of telomerase [79] especially since the ability to synthesize
new telomeric repeats is essential for the mutant TR-
dependent effects.
Furthermore, Massard et al. [80] demonstrated that TERT
repression may constitute a promising strategy for facilitat-
ing the induction of the mitochondrial pathway of apoptosis.
Other researchers showed that BIBR1532 (2-[(E)-3-
naphtalen-2-yl-but-2-enoylamino]-benzoic acid)-treated
cells show progressive telomere shortening, decreased pro-
liferative capacity, and sensitization to chemotherapeutic
treatment [81]. It was postulated to be provoked by potent,
selective, and reversible inhibitory action on human telome-
rase activity. This suggested that pharmacological telome-
rase inhibition in combination therapy may be a valid
strategy for the treatment of both drug-sensitive and drug-
resistant breast cancers. Interestingly, the combined effect of
low-dose doxorubicin and siRNA inhibition of telomerase
on breast cancer cells caused a rapid and potent apoptosis
induction in breast cancer cells. The effect of doxorubicin
was potentiated by the RNA interference directed against
telomerase subunits [82]. Although numerous telomerase
inhibition strategies cause cancer cells to undergo apoptosis
or senescence, there is often a lag period between the be-
ginning of the treatment regimen and a biological effect.
Thus, much better perspectives are expected when applying
effective telomerase inhibitors together with standard che-
motherapeutic agents, Doxorubicin/Adriamycin or Taxol.
Such attitude is supposed to provoke an increased sensitiza-
tion and efficacy for triggering senescence and/or apoptosis in
cultures of breast cancer cells while reducing toxicity [83].
First trials with oligonucleotides against telomerase
showed that methoxyethyl oligomers (2′-O-methoxyethyl
oligonucleotide) directed against the template region of telo-
merase are potent agents and that significant antiproliferative
effects can be observed after 2–3 weeks of treatment. Reduced
cell proliferation and tumor growth support the hypothesis that
telomerase inhibition can make a useful contribution to che-
motherapy and should encourage broad testing of telomerase
inhibitors [84]. One of the most advanced telomerase-
targeting strategies against cancer are represented by Geron
(Menlo Park, Ca, USA). The technology being at the clinical
trials at the moment is based on the oligonucleotides, called
imetelstat sodium (originally known as GRN163L).
GRN163L, a telomerase template antagonist, was effective
in inhibiting telomerase activity and shortening telomeres in
HER2-positive breast cancer cells [85]. It acts synergistically
with trastuzumab in inhibiting HER2-positive MDA-MB-231
breast cancer cell growth. More importantly, it was shown that
GRN163L can restore the sensitivity of therapy-resistant
breast cancer cells to trastuzumab. These findings implicate
that telomerase template antagonists might have a potential
use in the treatment of cancers that have developed resistance
to traditional cancer therapy [86]. It was also reported that
breast cancer cells treated with GRN163L exhibited signifi-
cantly diminished invasive potential [87]. As shown, long-
term continuous treatment of cells with GRN163L results in
progressive telomere shortening. It demonstrated that transient
inhibition of telomerase activity by the specific inhibitor,
GRN163L, increased the cytotoxicity of some, but not all,
DNA-damaging agents. These results suggest that the protec-
tive role of telomerase in cell cycle-restricted DNA damage
repair could be exploited for combined anticancer chemother-
apy [88]. Recently, it was reported that Phase I clinical trials in
breast cancer patients treated with GRN163L were success-
fully completed and the agent was selected for Phase II
clinical trials. As it was demonstrated, the compound is char-
acterized by promising bioavailability and pharmacokinetics.
Phase II tests are currently ongoing and Imetelstat is tested in a
combination with standard chemotherapeutic drugs
(bevacizumab and paclitaxel) in a group of patients with
locally relapsing or metastatic breast cancer [89].
Another group of telomerase-targeting drugs demonstrated
by Geron are telomerase cancer vaccines—GRNVAC1 and
GRNVAC2. They are autologous products consisting of ma-
ture dendritic cells (antigen-presenting cells) pulsed with RNA
for the protein component of human telomerase (TERT) and a
portion of a lysosomal targeting signal (LAMP). GRNVAC1 is
injected into the patient’s skin. From there, the dendritic cells
travel to the lymph nodes and instruct cytotoxic T cells to kill
tumor cells that express telomerase. Alternatively, Geron pro-
posed another solution (GRN1005) based on peptide technol-
ogy to facilitate the transfer of anticancer compounds across
the blood–brain barrier (BBB) to enable the treatment of
primary brain cancers and cancers that have metastasized to
the brain. It is not connected with telomerase directly; however,
due to the connection of telomerase with multidrug resistance,
this mechanism of action cannot be totally excluded [85]. It is
known that telomerase can function in a number of alternative
signaling mechanisms and some of them could be involved in
chemotherapeutic resistance, including DNA damage re-
sponse, and DNA repair [90]. Thus, it is suggested that
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upregulation of telomerase itself, independent of its role in
telomere maintenance, is capable of providing an alternative
pathway to drug resistance that does not require elongating
telomere lengths [83]. In the light of carcinogenesis complexity
and the contribution of mutations in many genes to the breast
cancer development [91], it should be emphasized that
monofunctional-targeted drugs will not cure most of the
patients with common carcinomas. Thus, the multifunctional
drugs or alternative treatment regimens are needed. Possibly
telomerase inhibitors could be administered as adjuvant therapy
in combination with conventional drugs to improve the effi-
ciency of chemotherapeutic agents used in the low doses.
Summary and conclusions—prospects for cancer
therapy
The expression of telomerase in various human cancers and its
diminished expression in most normal cells suggest that the
enzymemight serve as a good target for anticancer drugs. Due
to telomerase inhibition, activity, or expression, these drugs
might kill tumor cells by allowing telomeres to shrink or by
provoking apoptosis. First of all, this process might have a
chance to be cell-specific without serious side effects (Fig. 1).
In contrast, most existing anticancer therapies disturb normal
cells as well as malignant ones and often show some serious
toxicity. Since telomerase seems to be a universal cancer
marker, the agents targeting the enzyme might work against
a broad spectrum of tumors. Nevertheless, a number of ques-
tions must be answered. For instance, researchers need to
determine which normal cells (beyond the few already iden-
tified) reveal telomerase expression/activity and in what ex-
tent. They also need to assess the importance of the enzyme to
those cells. Telomerase-inhibiting agents might cause cancer
cells to lose their telomeres and die well before normal cells,
with their much longer telomeres, lose enough of their telo-
meres to suffer any ill effects. It should be unquestionably
demonstrated that inhibition of telomerase can destroy
telomerase-producing tumors as expected. Another problem
might be the delivery of telomerase-targeting agents in a way
that would provide high efficiency and specificity. Therapeu-
tic potential of vaccination has been explored in many clinical
trials involving patients with breast cancer. A large variety of
cancer immunogens have been tested. The majority of clinical
vaccination studies have been carried out in patients with
metastatic breast cancer, characterized by extremely aggres-
sive malignant tumors, resistant to all standard cytotoxic treat-
ments, and with longest-lasting disease. However, it is unclear
whether therapeutic vaccines for cancer prolong survival.
Data of clinical activity have been observed by using vaccines
targeting HER-2/neu protein, human telomerase reverse tran-
scriptase, carcinoembryonic antigen, and carbohydrate anti-
gen given after stem cell rescue [92].
Intensive studies of telomerase functioning in human
cells gave new perspectives on the mechanism of senes-
cence, stem cells, and cancer therapy. The studies show that
numerous enzymes are required for telomerase functioning
that facilitate new approaches for inhibiting telomerase in
treating cancer. Probably there are still numerous unrevealed
proteins that contribute to regulation of such a dynamic
complex. Anyway, it is still supposed to use both, activity
and expression regulation methods, as adjuvant therapies
similarly to G-quadruplex stabilization. Understanding of
telomerase activity may then bring a new insight into many
serious clinical problems that we have to face in aging
societies especially since telomerase might be also considered
as a predictive marker maybe even inmalignant transformation.
It is still unclear whether telomerase inhibitors will become a
treatment option against cancer. There is concern about the
alternative mechanisms of telomere maintenance and whether
there will be side effects on normal, hematopoietic, and
germline cells. These questions, however, can be only answered
if those drugs are moved into animal and human clinical trials.
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